Hong Kong, 27 May 2026 – WUXI BIO disclosed a fresh round of capital movements, combining a targeted share repurchase with modest share option exercises.

Share buy-back • On 27 May 2026 the company repurchased 1.47 million ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$33.54 to HK$34.50, for a total consideration of HK$49.91 million. • The repurchased shares, representing 0.04 % of the company’s issued share capital, are earmarked for cancellation. • Since the current mandate was approved on 6 June 2025, WUXI BIO has bought back 24.65 million shares, equivalent to 0.61 % of the shares outstanding on the mandate date. The company remains authorised to repurchase up to 406.87 million shares. • In accordance with Hong Kong Listing Rules, no new share issuance or sale/transfer of treasury shares may occur before 26 June 2026 (30 days after the latest repurchase) without Stock Exchange approval.

Option-driven share issuance • Between 8 and 26 May 2026, employees (excluding directors) exercised options granted under the 2016 Pre-IPO Share Option Scheme, leading to the issue of 76,800 new ordinary shares. • Exercise prices ranged from HK$1.71 to HK$2.64 per share. • These issuances expanded the company’s issued share base by 0.0019 %, lifting total outstanding shares (excluding treasury shares) from 4,140.82 million to 4,140.90 million.

Capital structure snapshot (post-events, pre-cancellation) • Issued shares: 4,140.90 million • Treasury shares: none • Shares pending cancellation: 1.47 million

Regulatory confirmations The board affirmed that all share issues and repurchases complied with Hong Kong Listing Rules, received full consideration, and met all necessary legal and procedural requirements.